Scientia Vascular, a Salt Lake City, UT-based commercial company offering a suite of interventional medical devices, raised $50M in growth equity financing.
The round was led by Vivo Capital.
The company intends to use the funds to accelerate sales, marketing, and new product development in both its core neurovascular stroke market as well as adjacent markets in peripheral vascular and interventional oncology.
Led by John Lippert, founder and CEO, Scientia is a pioneer in microfabrication technology and the company has used their core expertise to create a suite of commercially available and pipeline products for the treatment of neurovascular disease, peripheral vascular disease and interventional oncology. The company designs, develops and manufactures from its headquarters and ISO 13485 facility in Salt Lake City, Utah.
FinSMEs
31/05/2021